Treatment of Drug-induced Myopathy in Chronic Glucocorticosteroid Use

Myopathy arising from prolonged glucocorticosteroid (GCS) exposure represents one of the more frequently encountered forms of drug-induced muscle disease. Recognising the causative agent and acting on its use is central to clinical management.

Clinical scenario

This protocol applies to patients presenting with myopathy in the setting of chronic glucocorticosteroid use. This represents the second and more frequently encountered form of drug-induced myopathy, directly linked to prolonged GCS exposure.

Approach overview

Management focuses on addressing the glucocorticosteroid regimen — options exist along a spectrum of GCS modification — alongside structured rehabilitative interventions.

Full regimen details, sequencing, and specific options are in the complete protocol ↓

Instant Access to Structured Evidence-Based Regimens

References

The second, more frequent type, is associated with chronic use of glucocorticosteroids (GCS).
Treatment consists of discontinuation, dose reduction, or conversion of GCS to non-fluorinated molecules (prednisolone, hydrocortisone) rather than fluorinated molecules (triamcinolone, dexamethasone).
Rehabilitation regimens and physical activity help manage symptoms.

DOI: 10.3390/biomedicines12050987

View source ↗